DK0832093T3 - Udtrykkelse af lipoproteiner - Google Patents

Udtrykkelse af lipoproteiner

Info

Publication number
DK0832093T3
DK0832093T3 DK96918793T DK96918793T DK0832093T3 DK 0832093 T3 DK0832093 T3 DK 0832093T3 DK 96918793 T DK96918793 T DK 96918793T DK 96918793 T DK96918793 T DK 96918793T DK 0832093 T3 DK0832093 T3 DK 0832093T3
Authority
DK
Denmark
Prior art keywords
protein
lipidated
disclosed
leader sequence
heterologous
Prior art date
Application number
DK96918793T
Other languages
English (en)
Inventor
Maryanne B Gray
Robert C Huebner
Lorne F Erdile
Donald J Warakomski
Robert S Becker
Derek L Pyle
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Application granted granted Critical
Publication of DK0832093T3 publication Critical patent/DK0832093T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK96918793T 1995-06-07 1996-06-05 Udtrykkelse af lipoproteiner DK0832093T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47578195A 1995-06-07 1995-06-07
US48637395A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
DK0832093T3 true DK0832093T3 (da) 2007-01-08

Family

ID=27044930

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96918793T DK0832093T3 (da) 1995-06-07 1996-06-05 Udtrykkelse af lipoproteiner

Country Status (13)

Country Link
EP (2) EP1741718A3 (da)
JP (1) JP4091112B2 (da)
AT (1) ATE339436T1 (da)
AU (1) AU721954B2 (da)
CA (2) CA2704354A1 (da)
DE (1) DE69636544T2 (da)
DK (1) DK0832093T3 (da)
ES (1) ES2271954T3 (da)
FI (1) FI974422A (da)
IL (1) IL118578A (da)
NO (2) NO324089B1 (da)
PT (1) PT832093E (da)
WO (1) WO1996040718A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
ZA964896B (en) * 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
ES2334185T3 (es) 1998-02-03 2010-03-05 Center For Disease Control And Prevention Proteina psaa lipidada recombinante, procedimientos de preparacion y uilizacion.
AU2003204215B2 (en) * 1998-02-03 2007-01-11 Aventis Pasteur Recombinant Lipidated PsaA Protein, Methods of Preparation and Use
ATE387502T1 (de) * 2000-02-28 2008-03-15 Novartis Vaccines & Diagnostic Hybride expression von neisseria proteinen
EP1311540B1 (en) 2000-08-18 2007-12-19 Research Foundation Of State University Of New York Altered ospa of borrelia burgdorferi
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
JP5024830B2 (ja) 2004-10-25 2012-09-12 ステーテンズ セーラム インスティテュート クラミジア・トラコマチス（Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓ）抗原のワクチンおよび診断への使用
ES2647070T3 (es) 2005-06-23 2017-12-19 Statens Serum Institut Vacunas para tuberculosis que comprenden antígenos expresados durante la fase de infección latente
US20070166275A1 (en) 2006-01-19 2007-07-19 Mary Kay Inc. Compositions comprising kakadu plum extract or acai berry extract
US20090324638A1 (en) * 2006-06-12 2009-12-31 Biopeptides Corp. Live bacterial vaccine
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2199303B1 (de) 2008-12-12 2013-06-05 Euroimmun Medizinische Labordiagnostika AG Polypeptide und Verfahren zur spezifischen Detektion von Antikörpern bei Patienten mit einer Borrelieninfektion
TR201903223T4 (tr) 2009-04-24 2019-03-21 Statens Seruminstitut Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı.
KR101772139B1 (ko) 2009-08-28 2017-08-28 마리 케이 인코포레이티드 피부 케어 제형
HRP20210242T4 (hr) 2010-08-23 2024-05-10 Wyeth Llc Stabilne formulacije antigena iz bakterije neisseria meningitidis rlp2086
CA2809758C (en) 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
EP4043029A1 (en) 2012-03-09 2022-08-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
KR102199096B1 (ko) 2013-09-08 2021-01-06 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CA3051801A1 (en) 2017-01-31 2018-08-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624926A (en) * 1981-01-02 1986-11-25 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
CA2032914A1 (en) * 1989-12-26 1991-06-27 Peter C.K. Lau Use of bacterial lipoprotein amino terminus in fusion plasmids for in vivo expression of lipid modified polypeptides
CA2084413A1 (en) * 1990-06-15 1991-12-16 Richard A. Flavell Compositions and methods for the prevention and diagnosis of lyme disease
JP3215109B2 (ja) * 1991-02-15 2001-10-02 ユーエイビー リサーチ ファウンデーション 肺炎球菌タンパクの構造遺伝子
ES2194010T3 (es) * 1991-10-22 2003-11-16 Symbicom Ab Mejoras en el diagnostico y profilaxis de la borrelia burgdorferi.
WO1994014318A1 (en) * 1992-12-24 1994-07-07 Medimmune, Inc. Method of protection against streptococcus pneumoniae with transformed mycobacteria

Also Published As

Publication number Publication date
AU721954B2 (en) 2000-07-20
EP0832093A4 (en) 2001-01-03
ATE339436T1 (de) 2006-10-15
NO324089B1 (no) 2007-08-13
JPH11514841A (ja) 1999-12-21
EP0832093A1 (en) 1998-04-01
JP4091112B2 (ja) 2008-05-28
WO1996040718A1 (en) 1996-12-19
PT832093E (pt) 2006-12-29
FI974422A0 (fi) 1997-12-05
IL118578A0 (en) 1996-10-16
CA2223300C (en) 2010-07-27
FI974422A (fi) 1998-02-04
IL118578A (en) 2006-12-31
EP1741718A3 (en) 2007-03-28
DE69636544T2 (de) 2007-06-06
CA2704354A1 (en) 1996-12-19
EP1741718A2 (en) 2007-01-10
AU6134396A (en) 1996-12-30
NO975619D0 (no) 1997-12-04
NO20064621L (no) 1998-01-30
CA2223300A1 (en) 1996-12-19
DE69636544D1 (de) 2006-10-26
NO975619L (no) 1998-01-30
ES2271954T3 (es) 2007-04-16
EP0832093B1 (en) 2006-09-13

Similar Documents

Publication Publication Date Title
NO20064621L (no) Ekspresjon av lipoproteiner.
TR199600084A2 (tr) Sismanlamaya karsi proteinler.
NO20004218L (no) Íkning av den sirkulerende halveringstiden til et antistoff- basert fusjonsprotein
NL1007028A1 (nl) Stabilisatorcombinatie.
FR2703239B1 (fr) Agrafe pour prothèse inter-épineuse.
DK0954588T3 (da) OB fusionsprotein-sammensætninger og fremgangsmåder
TR199600357A2 (tr) Rekombinant simanlik (Ob) proteinleri.
DE69735926D1 (de) Interleukin-18 Rezeptorproteine
DE69708120T2 (de) Laser-absorbierende, lichtbleichbare zusammensetzungen
EP0608120A3 (en) Flow control device for capillary electrophoresis.
ID29065A (id) Penghambat-penghambat farnesil protein transferase
FR2702361B1 (fr) Fixateur pour les ostéosynthèses lombo-sacrées.
DE69528180D1 (de) Modifiziertes molkeprotein
IT1307309B1 (it) Peptidi stabilizzanti, polipeptidi ed anticorpi che li comprendono.
DE69933509D1 (de) Roboter Steuerungssystem
DE19681312T1 (de) Datenverbindungs-Steuerverfahren
FI980735A (fi) Viiveenhallintamenetelmä
FR2710021B1 (fr) Selle perfectionnée.
SE9003374D0 (sv) A collagen binding protein as well as its preparation
TR27243A (tr) Antimikrobiyal proteinler.
ITRM930616A0 (it) Dispositivo perfezionato per il controllo di saldatura.
NL1005505A1 (nl) Servobesturingsinrichting.
DE59701374D1 (de) Kontrollsystem für zwei einander dicht zugeordnete, voneinander lösbare teile
NL1005018A1 (nl) Tweesporig geleidingssysteem.
FI970906A0 (fi) Säätelymenetelmä